Loading clinical trials...
Loading clinical trials...
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN
Conditions
Interventions
Placebo to Week 16; tanezumab 5mg SC
Placebo to Week 16, tanezumab 10 mg SC
+3 more
Locations
262
United States
Central Alabama Research
Birmingham, Alabama, United States
Cahaba Research
Birmingham, Alabama, United States
Alabama Clinical Research, LLC
Mobile, Alabama, United States
Alabama Orthopaedic Clinic, P.C.
Mobile, Alabama, United States
Coastal Clinical Research
Mobile, Alabama, United States
Horizon Research Partners, LLC
Mobile, Alabama, United States
Start Date
August 18, 2015
Primary Completion Date
October 17, 2017
Completion Date
December 20, 2018
Last Updated
February 21, 2020
NCT06821607
NCT07543952
NCT07282925
NCT07467070
NCT06661850
NCT03836248
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions